| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -41,487 | -30,260 |
| Depreciation and amortization | 721 | 494 |
| Stock-based compensation | 7,336 | 5,200 |
| Amortization of premiums and discounts on marketable securities | 1,769 | 1,275 |
| Amortization of debt discount and issuance costs and other non-cash interest | 238 | 201 |
| Impairment loss of right-of-use asset | 0 | 0 |
| Reclassification of currency translation loss | 282 | - |
| Gain on disposition of fixed assets | 4 | - |
| Prepaid expenses and other current assets | -958 | -1,390 |
| Other assets | -2,415 | -1,741 |
| Accounts payable, accrued and other current liabilities | -6,748 | -6,322 |
| Operating lease assets and liabilities | 1,757 | 1,154 |
| Net cash used in operating activities | -39,815 | -29,985 |
| Purchases of property and equipment | 8 | 8 |
| Proceeds from sale of fixed assets | 9 | - |
| Purchases of marketable securities | 42,631 | 28,334 |
| Maturities of marketable securities | 83,481 | 53,481 |
| Net cash provided by investing activities | 40,851 | 25,139 |
| Repayment of loan principal | 3,913 | 2,608 |
| Proceeds from issuance of common stock under employee stock incentive plans | 35 | 35 |
| Net cash (used in) provided by financing activities | -3,878 | -2,573 |
| Effect of exchange rate changes on cash and cash equivalents | 28 | 37 |
| Net decrease in cash and cash equivalents | -2,814 | -7,382 |
| Cash and cash equivalents at beginning of period | 41,749 | - |
| Cash and cash equivalents at end of period | 38,935 | - |
Kezar Life Sciences, Inc. (KZR)
Kezar Life Sciences, Inc. (KZR)